PALISADE BIO, INC. Accounts Payable
PALISADE BIO, INC. (PALI) had Accounts Payable of $1.83 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-10
- 2026-06-30: Accounts Payable, Current $1.83M.
- 2026-03-31: Accounts Payable, Current $2.70M.
- 2025-12-31: Accounts Payable, Current $767.00K.
- 2025-09-30: Accounts Payable, Current $1.43M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $1.83M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $767.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | $1.43M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.37M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $745.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.10M 10-K · filed 2026-03-20 |
| 2024-09-30 | $366.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $514.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $459.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $698.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $950.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $922.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $706.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.76M 10-K · filed 2024-03-26 |
| 2022-09-30 | $1.73M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.04M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.15M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $1.32M 10-K · filed 2023-03-22 |
| 2021-09-30 | $1.38M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $1.41M 10-Q · filed 2021-08-23 |
| 2020-12-31 | $2.54M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |